Skip to main content

Novel Rx

      In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.
      Autoinflammatory/Still's Disease Panel - EULAR2020

      Drs. Olga Petryna, Petros Efthimiou, Apostolos Kontzias and Jack Cush discuss autoinflammatory highlights from the Virtual EULAR 2020 meeting June 3-6

      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      Gout Review from EULAR2020

      Dr. Olga Petryna reviews highlights from the virtual EULAR 2020 meeting June 3-6, 2020

      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.
      SELECT-Choice: UPA vs ABA in RA

      Dr. Jack Cush from EULAR2020 Virtual Conference

      OP0151

      GCA and Risk of Cancer or Visual Loss

      Dr. Olga Petryna from EULAR2020 Virtual Conference

      OP0149 Tocilizumab Treats Visual Loss in GCA

      OP0143 GCA in Israel and risk of Cancer

      MSK Flares with Vedolizumab

      Dr. Rachel Tate from EULAR2020 on Abstract FRI0294

      Bimekizumab in Ankylosing Spondylitis

      Dr. Rachel Tate from EULAR2020 Virtual Conference

      Biosimilars in Spondyloarthritis

      Dr. Rachel Tate from EULAR2020 Virtual Conference 0632

      - ETN Biosimilar in Reactive Arthritis 0650

      - Treasure Study in infliximab biosimilar in SpA

      Enticing New Options in ANCA-Associated Vasculitis

      Dr. David Liew from EULAR2020 ANCA-Associated Vasculitis Avacopan vs Prednisone MAINRITSAN 2 study - Calprotectin

      RT @DrPetryna: #EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly bett

      Olga Petryna DrPetryna

      5 years 1 month ago
      #EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU
      RT @DrPetryna: #eular2020 #op0205 phase 1 trial of novel URAT1 inhibitor D-0120 in healthy adults: safe up to 20 mg/d af

      Olga Petryna DrPetryna

      5 years 1 month ago
      #eular2020 #op0205 phase 1 trial of novel URAT1 inhibitor D-0120 in healthy adults: safe up to 20 mg/d after 7 days. Significant reduction of sUA peaks at 4-8h & lasts up to 24h @RheumNow
      ×